Sitagliptin
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for type 2 diabetes. It enhances the body's incretin system to improve glycemic control. It is well tolerated, weight-neutral, and has a low risk of hypoglycemia, making it a useful add-on therapy to metformin or other agents.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for type 2 diabetes. NutriStack rates the supporting evidence as strong. Common adult dosing is 100 mg once daily; dose adjustment for renal impairment: 50 mg (eGFR 30–45) or 25 mg (eGFR <30) (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c by 0.5–0.8%, weight neutral, low risk of hypoglycemia as monotherapy. 10 sources indexed (2012–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Selectively and reversibly inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which normally degrades the incretin hormones GLP-1 and GIP. By prolonging incretin activity, sitagliptin enhances glucose-dependent insulin secretion from beta cells and suppresses glucagon release from alpha cells, lowering both fasting and postprandial glucose in a glucose-dependent manner.7
Dosing & protocol.
Can be taken with or without food. No significant food interactions.
Full safety detail.
Side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Headache
- Joint pain (arthralgia)
- Pancreatitis (rare but serious)
- Bullous pemphigoid (rare)
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
4- 1Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta-AnalysisPMIDAshraf S, Burhan M, Sarwar S et al. · Endocrinology, diabetes & metabolism · 2026
Ashraf S, Burhan M, Sarwar S et al.. Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta-Analysis. Endocrinology, diabetes & metabolism. 2026
- 2Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisPMIDZhang Y, Cai T, Zhao J et al. · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2020
Zhang Y, Cai T, Zhao J et al.. Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2020
- 3Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysisPMIDDu Q, Wu B, Wang YJ et al. · Current medical research and opinion · 2013
Du Q, Wu B, Wang YJ et al.. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Current medical research and opinion. 2013
- 4Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysisPMIDGerrald KR, Van Scoyoc E, Wines RC et al. · Diabetes, obesity & metabolism · 2012
Gerrald KR, Van Scoyoc E, Wines RC et al.. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes, obesity & metabolism. 2012
Randomized controlled trials
1- 5Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trialPMIDHong EG, Min KW, Chun S et al. · Diabetes, obesity & metabolism · 2025
Hong EG, Min KW, Chun S et al.. Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial. Diabetes, obesity & metabolism. 2025
Reference material
5- 6Green JB et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes (TECOS). N Engl J Med. 2015;373(3):232-242.Source linkedPMID
- 7Aschner P et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637.Source linkedPMID
- 8Wu Y et al. Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis. BMC Med. 2026.Source linkedPMID
- 9Singh AK, Das AK, Murthy LS et al.. Efficacy of Dapagliflozin + Sitagliptin + Metformin Versus Sitagliptin + Metformin in T2DM Inadequately Controlled on Metformin Monotherapy: A Multicentric Randomized Trial. Advances in therapy. 2025Source linkedPMID
- 10Seino Y, Terauchi Y, Osonoi T et al.. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes, obesity & metabolism. 2018Source linkedPMID
Common questions.
Quick answers about Sitagliptin, drawn from the data on this page.
What is Sitagliptin?
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for type 2 diabetes. It enhances the body's incretin system to improve glycemic control. It is well tolerated, weight-neutral, and has a low risk of hypoglycemia, making it a useful add-on therapy to metformin or other agents.
What is Sitagliptin used for?
Commonly cited benefits of Sitagliptin include: Lowers HbA1c by 0.5–0.8%; Weight neutral; Low risk of hypoglycemia as monotherapy; Once-daily oral dosing; Well tolerated with few GI side effects. NutriStack rates the overall evidence as strong.
What is a typical dose of Sitagliptin?
A typical adult dose of Sitagliptin is 100 mg once daily; dose adjustment for renal impairment: 50 mg (eGFR 30–45) or 25 mg (eGFR <30) (as prescribed by your physician). The commonly recommended form is Oral tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Sitagliptin?
Reported side effects include upper respiratory tract infection, nasopharyngitis, headache, joint pain (arthralgia), pancreatitis (rare but serious), bullous pemphigoid (rare). This is educational information; check with a healthcare professional before use.
How strong is the evidence for Sitagliptin?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Sitagliptin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.